Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2′-deoxyguanosine

Cancer Discovery

Volumn 5, Issue 1, 2015, Pages 82-95

  Mender, Ilgen ^a,b   Gryaznov, Sergei ^c   Dikmen, Z Gunnur ^b   Wright, Woodring E ^a   Shay, Jerry W ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c AuraSense Therapeutics   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIO 2' DEOXYGUANOSINE; ASPARTATE AMINOTRANSFERASE; DIMETHYL SULFOXIDE; KI 67 ANTIGEN; PURINE NUCLEOSIDE; TELOMERASE; TIOGUANINE; UNCLASSIFIED DRUG; ALPHA-2'-DEOXYTHIOGUANOSINE; DEOXYGUANOSINE; NUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLOOD SAMPLING; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL DEATH; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DNA ISOLATION; DRUG SCREENING; DRUG TOXICITY; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; TELOMERE; TELOMERE DYSFUNCTION INDUCED FOCI ASSAY; TELOMERE LENGTH ASSAY; TELOMERE SHORTENING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CELL TRANSFORMATION; DNA DAMAGE; DRUG EFFECTS; ENZYME SPECIFICITY; GENETICS; KIDNEY; LIVER; METABOLISM; PATHOLOGY; TELOMERE HOMEOSTASIS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DEOXYGUANOSINE; DNA DAMAGE; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; HETEROGRAFTS; HUMANS; KIDNEY; LIVER; MICE; SUBSTRATE SPECIFICITY; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; THIOGUANINE; THIONUCLEOSIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922365281     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0609     Document Type: Article

References (35)

1. Naito T, Matsuura A, Ishikawa F. Circular chromosome formation in a fission yeast mutant defective in two ATM homologues. Nat Genet 1998; 20: 203-6.
2. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.
3. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-10.
4. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972; 239: 197-201.
5. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996; 8: 66-71.
6. Shay JW, Wright WE. Telomeres and telomerase: implications for cancer and aging. Radiat Res 2001; 155: 188-93.
7. Shay JW, Wright WE, Werbin H. Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta 1991; 1072: 1- 7.
8. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-7.
9. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-73.
10. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 2004; 64: 3444-51.
11. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol 2011; 21: 349-53.
12. Gryaznov SM, Jackson S, Dikmen G, Harley C, Herbert BS, Wright WE, et al. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids 2007; 26: 1577-9.
13. D jojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005; 42: 1127-36.
14. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 2006; 12: 3184-92.
15. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006; 96: 73-81.
16. Williams SC. No end in sight for telomerase-targeted cancer drugs. Nat Med 2013; 19: 6.
17. Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, et al. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res 2013; 19: 6578- 84.
18. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-56.
19. de Lange T. Protection of mammalian telomeres. Oncogene 2002; 21: 532-40.
20. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATMdependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321-5.
21. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8: 24-36.
22. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25: 1629-38.
23. Gunnarsdottir S, Elfarra AA. Distinct tissue distribution of metabolites of the novel glutathione-activated thiopurine prodrugs cis-6-(2-acetylvinylthio)purine and trans-6-(2-acetylvinylthio)guanine and 6-thioguanine in the mouse. Drug Metab Dispos 2003; 31: 718- 26.
24. Tendian SW, Parker WB. Interaction of deoxyguanosine nucleotide analogs with human telomerase. Mol Pharmacol 2000; 57: 695-9.
25. Stefl R, Spackova N, Berger I, Koca J, Sponer J. Molecular dynamics of DNA quadruplex molecules containing inosine, 6-thioguanine and 6-thiopurine. Biophys J 2001; 80: 455-68.
26. Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 2010; 70: 6268-76.
27. Tang B, Testa JR, Kruger WD. Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells. Cancer Biol Ther 2012; 13: 1082-90.
28. Brem R, Karran P. Oxidation-mediated DNA cross-linking contributes to the toxicity of 6-thioguanine in human cells. Cancer Res 2012; 72: 4787- 95.
29. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
30. Rao TS, Durland RH, Seth DM, Myrick MA, Bodepudi V, Revankar GR. Incorporation of 2′-deoxy-6-thioguanosine into G-rich oligodeoxyribonucleotides inhibits G-tetrad formation and facilitates triplex formation. Biochemistry 1995; 34: 765-72.
31. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11: S27-31.
32. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS, et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007; 8: 497-503.
33. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007; 11: 461- 9.
34. Suram A, Kaplunov J, Patel PL, Ruan H, Cerutti A, Boccardi V, et al. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J 2012; 31: 2839-51.
35. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-91.